ABOUT THAERAPY
Our inhalation treatments are aiming to enable patients to regain control of daily activities and therefore rebuilding confidence. To achieve this, we are developing improved treatments for indications with high unmet medical need by optimizing drug-device combinations. Finally, we will seek approval for these products through meaningful clinical trials in collaboration with patient organizations and physicians.
Thaerapy focuses on aerosol-based treatments, recognizing the efficacy of inhalation for certain diseases affecting the lungs or the pulmonary circulation. Our initial product TRP-001 targets Pulmonary Arterial Hypertension (PAH).
ABOUT Pulmonary Arterial hypertension
In pulmonary arterial hypertension (PAH), lung blood vessels are narrowed, blocked, or damaged, resulting in reduced blood flow and increasing pressure. This puts strain on the heart, causing fatigue and limiting daily activities. Eventually, the heart weakens and fails.
Although there are existing treatments for reducing symptoms and addressing improvement of exercise capacity available, they currently all aim for daily maintenance therapy.
However, as most patients are telling, there are still situations where these treatments are not fully addressing their symptoms and an additional "on the spot” treatment with a fast onset is needed for short-term reduction of symptoms and increase of exercise capacity.
OUR PRODUCT:TRP-001
Thaerapy develops a fast-acting, “on-the-spot” treatment for rapid relief of PAH symptoms and to improve the patient’s exercise capability. In medical terms such a treatment that patients only take when they need it, is named a ‘pro re nata’ or PRN treatment.
TRP-001, our inhaled Treprostinil for pulmonary arterial hypertension, which is currently in development, repurposes a well-known drug. It will be conveniently delivered via a pocket-sized soft mist inhaler from our device partner Resyca, allowing patients to carry it aroundand to use it as needed in addition to their existing maintenance therapy.
pipeline
Thaerapy is currently working on two aerosol drug device combination products, the main focus being on TRP-001.
FAQ
Everything you need to know about the product. Can’t find the answer you’re looking for? Please contact our team.
Contact us
